News

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

Phase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.

Christine A. Curcio, PhD, shares an update on histology and its critical role in advancing <3 μm optical coherence tomography interpretation

Insights on injection technique and the future potential of SCS treatments.

The trial is evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa

ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently with no current FDA-approved therapy

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients

Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, administered as an eye drop for the treatment of presbyopia.

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.

Johann Krüger, MD, shares insights from 26 years of experience

PYC Therapeutics advances VP-001 for retinitis pigmentosa, securing FDA guidance for its upcoming registrational trial design and study parameters.

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Breye Therapeutics advances danegaptide, a novel oral therapy for non-proliferative diabetic retinopathy, showing promise in early clinical trials.

Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials

Andrew G. Lee, MD, and Drew Carey, MD, discuss how baseline optical coherence tomography parameters can help ophthalmologists counsel patients and make more informed decisions after ethambutol-associated optic neuropathy.

The global prevalence of myopia has surged, and is expected to affect nearly 5 billion people by 2050

Baljean Dhillon, FRCPS, FRCS, FRCOphth, FRCPE, advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium.

Make the most of your practice and your retina conference participation.

Intracameral tPA can treat fibrinous clots in severe anterior uveitis.

The framework covers ocular hypertension to severe progression

Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and patient experience.

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Changing demographics and increasing trial complexity present challenges and opportunities.

The report divides the research into 7 categories: sex, gender, and hormones; epidemiology; pathophysiology; tear film; pain and sensation; iatrogenic; and clinical trial design.

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).

Patients in Ontario expose illegal user fees for cataract surgeries in private clinics, urging government action to uphold the Canada Health Act.